NCT05322005View on ClinicalTrials.gov

Study of Clinical Performance and Safety of Treatments in Degenerative Meniscopathy With Injection of Polynucleotides

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

July 27, 2024

Study Completion Date

July 27, 2024

Conditions

Meniscus TearMeniscus Lesion

Interventions

PROCEDURE

partial meniscectomy

Arthroscopic procedure

DEVICE

Condrotide® (polynucleotides gel: class III medical device)

Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Trial Locations (2)

2100

Peter Verdonk, Deurne

20089

Elizaveta Kon, Milan

All Listed Sponsors

lead

Mastelli S.r.l

INDUSTRY

NCT05322005 - Study of Clinical Performance and Safety of Treatments in Degenerative Meniscopathy With Injection of Polynucleotides | Biotech Hunter | Biotech Hunter